Advancements in breast cancer treatment are steering the medical community towards more patient-centric approaches, with emphasis on maintaining oncologic outcomes while reducing the burden on patients. One significant change involves the omission of axillary lymph node dissection (ALND) in patients with early-stage breast cancer. Recent studies, including the SOUND and INSEMA trials, provide evidence that supports this less invasive procedure in select cases.

The Historical Context of Aggressive Treatment

In the past, breast cancer treatment was characterized by comprehensive approaches that often included surgical removal of the breast (mastectomy), extensive chemotherapy, and radiation therapy. While these methods have been effective, they come with substantial side effects and can significantly impact patients’ quality of life.

The Evolution of Breast Cancer Management

“The traditional treatment methods had high burdens,” stated Dr. Monica Morrow from Memorial Sloan Kettering Cancer Center. “Research over the years has shown that breast conservation surgery can be as effective as mastectomy, sentinel lymph node biopsy (SLNB) can replace full axillary dissection, and targeted therapies are often more effective than chemotherapy.”

SOUND and INSEMA: Key Studies on Omitting Axillary Surgery

The SOUND trial, a phase III study, divided early-stage breast cancer patients with negative axillary ultrasounds into two groups: one receiving SLNB and the other undergoing no axillary surgery. Data from this trial revealed that the 5-year disease-free survival rates were comparable between groups, and axillary recurrence was minimal in both.

Similarly, the INSEMA trial highlighted that patients who skipped SLNB experienced reduced rates of lymphedema, restricted arm movement, and pain, without compromising their outcome.

Real-World Application and Criteria

Dr. Elizabeth Mittendorf from Dana-Farber Cancer Institute implemented these findings into their practice, developing specific criteria to determine when patients are candidates for omitting SLNB. According to Mittendorf, patients in the age range of 60 to 69, with T1N0 tumors, ductal histology, grade 1-2 disease, estrogen receptor levels above 10%, and negative axillary ultrasound, may qualify.

Subgroup Suitability for Omitting SLNB

In her presentation, Dr. Mittendorf emphasized that the criteria were primarily designed to fit older women who are candidates for partial breast irradiation after surgery. Dr. Toralf Reimer of the University of Rostock further elaborated on this point, proposing that patients aged 50 and older with HR-positive breast cancer and tumors less than or equal to 2 cm could also benefit from reduced surgical intervention.

Challenges and Considerations

Despite the promising findings, some questions remain unanswered. For instance, the role of preoperative imaging in SLNB omission is still a subject of debate. Additionally, the appropriate strategy for patients with non-HR-positive/HER2-negative tumors undergoing upfront surgery has not been fully clarified.

“Shared decision-making with patients and a multidisciplinary team is essential to determine the best treatment plan without risking their care,” advised Dr. Puneet Singh of the University of Texas MD Anderson Cancer Center. Dr. Singh also discussed the potential implications for adjuvant therapies based on the rate of sentinel node positivity in patients with larger tumors.

The Impact of Choosing Wisely Recommendations

Mittendorf’s research aligns with the Choosing Wisely campaign, which promotes the omission of SLNB in patients aged 70 and older. This approach is beneficial in reducing the incidence of side effects associated with lymph node dissection, such as lymphedema.

Conclusion: Balancing Oncologic Outcomes and Patient Well-being

The findings from the SOUND and INSEMA trials mark a significant step forward in tailoring breast cancer treatment to individual patient needs. By reducing unnecessary procedures and minimizing their associated side effects, healthcare providers can improve the overall quality of life for breast cancer patients while preserving oncologic outcomes. As further research continues to expand our understanding of these advancements, shared decision-making and multidisciplinary approaches will be crucial in optimizing patient care.

Comment below with your thoughts on the future of breast cancer treatment and how these advancements might influence your personal or professional experience.

We invite you to:

• Share your insights and experiences in the comments section below.
• Subscribe to Archynetys for more updates on cancer research, treatments, and patient care.
• Like and share this article on your social media channels to spread the word and engage with our community.